Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Despite the UK’s potential as an international life sciences leader, it lags many competitors ...

A lot has changed in clinical trial transparency since Project Data Sphere outlined plans to share cancer results in 2012, with the European law voted in last week ...

Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making. An analysis of 10 years of decision-making by health ...

Link to Fitch Ratings' Report: Sovereign Data Comparator - December 2013LONDON, December 06 (Fitch) Fitch Ratings has published the December edition of its Sovereign Data Comparator. The report is ...

(RTTNews) - Eli Lilly and Co. (LLY) said that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3 TRAILBLAZER-ALZ 4 study, providing the first ...

- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm ® (aducanumab-avwa)-treated patients at 6 months - Donanemab reduced ...